Author

J. L. Dahlin

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Approach:Bayesian inference· 1 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

J. H. Shrimp· 2 shared S. L. Schreiber· 2 shared A. Agrawal· 1 shared A. D. White· 1 shared A. E. Carpenter· 1 shared A. G. Godfrey· 1 shared A. G. Reidenbach· 1 shared A. I. Chan· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

J. H. Shrimp

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Nonspecific membrane bilayer perturbations by ivermectin underlie SARS-CoV-2 in vitro activity

R. T. Eastman, R. Rusinova, K. F. Herold, X.-P. Huang, P. Dranchak, T. C. Voss, S. Rana, J. H. Shrimp, A. D. White, H. C. Hemmings, B. L. Roth, J. Inglese, O. S. Andersen, J. L. Dahlin

This study shows ivermectin reduces SARS-CoV-2 viral burden in vitro but at concentrations that also cause cytotoxicity, suggesting its antiviral effect may be due to nonspecific membrane perturbation rather than specific antiviral activity.

bioRxiv · Oct 23, 2023 · PreprintPharmacology & Toxicology

Reference compounds for characterizing cellular injury in high-content cellular morphology assays

J. L. Dahlin, B. K. Hua, B. E. Zucconi, S. D. Nelson, S. Singh, A. E. Carpenter, J. H. Shrimp, E. Lima-Fernandes, M. J. Wawer, L. P. Chung, A. Agrawal, M. O'Reilly, D. Barsyte-Lovejoy, M. Szewczyk, F. Li, , B. K. Wagner

The paper profiles 218 cytotoxic and nuisance compounds in U-2 OS cells to create reference compounds for improving assay optimization and compound prioritization in cellular morphology assays.

bioRxiv · Jul 12, 2022 · PreprintPharmacology & Toxicology

Cross-platform Bayesian optimization system for autonomous biological assay development

S. Elder, C. Klumpp-Thomas, A. Yasgar, J. Travers, S. Frebert, K. M. Wilson, A. V. Zakharov, J. L. Dahlin, C. Kreisbeck, D. Sheberla, G. S. Sittampalam, A. G. Godfrey, A. Simeonov, S. Michael

This paper develops a cross-platform Bayesian optimization system to accelerate biological assay development, reducing costs and time compared to brute force methods.

bioRxiv · Jun 23, 2021Biochemistry

Multimodal small-molecule screening for human prion protein binders

A. G. Reidenbach, M. F. Mesleh, D. Casalena, S. M. Vallabh, J. L. Dahlin, A. J. Leed, A. I. Chan, D. L. Usanov, J. B. Yehl, C. T. Lemke, A. J. Campbell, R. N. Shah, O. K. Shrestha, J. R. Sacher, V. L. Rangel, , E. V. Minikel

This study screens for small-molecule binders of the human prion protein using multiple methods but finds only a weak binder with no therapeutic potential.

bioRxiv · Jun 18, 2020Biochemistry